

THE STATE OF TUBERCULOSIS, NEW YORK CITY 2015


Joseph Burzynski, MD, MPH Assistant Commissioner Bureau of Tuberculosis Control


Core TB Control Activities Screen for, diagnose & treat TB in our Chest Centers Ensure patients receive the best possible care and can complete treatment (case management, medical consultation) Prevent transmission and identify those who need treatment (contact investigation, outbreak detection) Maintain a registry of confirmed and suspected cases and contacts Conduct analysis and evaluation to inform best practices Collaborate with community-based organizations and other agencies































































Epidemiologic investigations in non-household settings by site type, number of exposed contacts, and transmission assessment, New York City, 2015 (n=48) School/ daycare (13%) 48 5 (19%) 1,133 204 1,337 1,091 (96%) 192 (94%) 1,283 (96%) 847 (78%) 173 (90%) 1,020 (80%) Tested 42 (5%) 22 (13%) 64 (6%)







2015 PUBLICATIONS	
2015 PUBLICATIONS	
Highlights	
6 6	



Risk for TB Disease Among Contacts with Pripositive Tuberculin Skin Test Risk factors for TB disease among contacts that tested prior positive Adjusted PR Contact under 5 years old at TB exposure 19.48 (7.15–53.0 Household contact Household contact 2.60 (1.30–5.21) Received ≥ 1 month of treatment for TB infection 0.27 (0.08–0.93) US born index patient 4.04 (1.95–8.38) Infectious index patient (smear + or cavities on CXR) 1.93 (1.01–3.71) • Among contacts with prior positive TST results, just 1.3% developed active TB disease and had genotyping results available • Healthcare providers should consider prophylaxis for contacts with prior TT infection, especially young children and close contacts of TB patients (e.g., especially young children and close contacts of the patients (and the patients)	
tested prior positive Image: Contact under 5 years old at TB exposure 19.48 (7.15–53.0 Household contact 2.60 (1.30–52.1) Household contact 2.60 (1.30–5.21) Received ≥ 1 month of treatment for TB infection 0.27 (0.08–0.93) US born index patient 4.04 (1.95–8.38) Infectious index patient (smear + or cavities on CXR) 1.93 (1.01–3.71) • Among contacts with prior positive TST results, just 1.3% developed active TB disease ≤ 4 years after exposure Genotype results were concordant with the index patients among 14 of 15 contact who developed active TB disease and had genotyping results available • Healthcare providers should consider prophylaxis for contacts with prior TI infection, especially young children and close contacts of TB patients (e.g., the second s	ior
Household contact 2.60 (1.30–5.21) Received ≥ 1 month of treatment for TB infection 0.27 (0.08–0.93) US born index patient 4.04 (1.95–8.38) Infectious index patient (smear + or cavities on CXR) 1.93 (1.01–3.71) • Among contacts with prior positive TST results, just 1.3% developed active TB disease ≤ 4 years after exposure 1.93 (1.01–3.71) • Genotype results were concordant with the index patients among 14 of 15 contact with of eveloped active TB disease and had genotyping results available • Healthcare providers should consider prophylaxis for contacts with prior TI infection, especially young children and close contacts of TB patients (e.g., patients (e.g., patients) (e.g.,	
Received ≥ 1 month of treatment for TB infection 0.27 (0.08–0.93) US born index patient 4.04 (1.95–8.38) Infectious index patient (smear + or cavities on CXR) 1.93 (1.01–3.71) • Among contacts with prior positive TST results, just 1.3% developed active TB disease ≤ 4 years after exposure 1.93 (1.01–3.71) • Genotype results are concordant with the index patients among 14 of 15 contact who developed active TB disease and had genotyping results available Healthcare providers should consider prophylaxis for contacts with prior TI infection, especially young children and close contacts of TB patients (e.g., patients)	.09)
US born index patient 4.04 (1.95–8.38) Infectious index patient (smear + or cavities on CXR) 1.93 (1.01–3.71) • Among contacts with prior positive TST results, just 1.3% developed active TB disease ≤ 4 years after exposure 1.93 (4.01 – 3.71) • Genotype results were concordant with the index patients among 14 of 15 contact who developed active TB disease and had genotyping results available • Healthcare providers should consider prophylaxis for contacts with prior TI infection, especially young children and close contacts of TB patients (e.g., the second sec)
Infectious index patient (smear + or cavities on CXR) 1.93 (1.01–3.71) • Among contacts with prior positive TST results, just 1.3% developed active TB disease ≤ 4 years after exposure • Genotype results were concordant with the index patients among 14 of 15 contact who developed active TB disease and had genotyping results available • Healthcare providers should consider prophylaxis for contacts with prior TI infection, especially young children and close contacts of TB patients (e.g., the second s	3)
 Among contacts with prior positive TST results, just 1.3% developed active TB disease ≤ 4 years after exposure Genotype results were concordant with the index patients among 14 of 15 contact who developed active TB disease and had genotyping results available Healthcare providers should consider prophylaxis for contacts with prior TI infection, especially young children and close contacts of TB patients (e.g., the second second	3)
 disease ≤ 4 years after exposure Genotype results were concordant with the index patients among 14 of 15 contac who developed active TB disease and had genotyping results available Healthcare providers should consider prophylaxis for contacts with prior TI infection, especially young children and close contacts of TB patients (e.g.,)
	гв
those with household exposure). Gounder et al. J Gen Intern Med. 2015	


Treatment for TB infection with three months of rifapentine and isoniazid


Characteristic	3HP	Other ¹	P-value ²
Total	302	92	-
Completed treatment	196 (65)	42 (46)	<0.01
Lost	31 (10)	23 (25)	<0.01
Refused	26 (9)	22 (24)	<0.01
Switched treatment	18 (6)	0 (0)	0.01
Discontinued due to side effects	13 (4)	0 (0)	0.04
Other	18 (6)	4 (4)	0.80
Unknown	0 (0)	1 (1)	0.23


 Implementation of 3HP increased treatment completion by 31%, but did not increase treatment acceptance
 In-clinic DOT requirement


was a major barrier to acceptance

 Side effects were generally mild; 13 patients (4%) permanently discontinued 3HP due to side effects









3/23/2016

QUESTIONS?